Skip to main content

View full-text article in PMC

. 2019 May 21;35:57–62. doi: 10.1016/j.coviro.2019.04.002

Table 1.

Nucleoside analogues with demonstrated activity against human CoVs

Nucleoside analogue	EC50 or IC50	Citation
Ribavirin	50–819 μM (SARS-CoV)	[21,51]
Ribavirin	20 μM (MERS-CoV)	[21,51]

Remdesivir	0.07 μM (SARS-CoV)	[17^••,32^••]
	0.03–0.07 μM (MERS-CoV)
	0.03 μM (MHV)

β-d-N4-hydroxycytidine	0.4 μM (HCoV-NL63)	[36,38]
β-d-N4-hydroxycytidine	5 μM (SARS-CoV)	[36,38]

BCX4430	68.4 μM (MERS-CoV)	[31]
BCX4430	57.7 μM (SARS-CoV)	[31]

Gemcitabine hydrochloride	1.22 μM (MERS-CoV)	[40]
Gemcitabine hydrochloride	4.96 μM (SARS-CoV)	[40]

6-Azauridine	0.03 μM (HCoV-NL63)	[36]

Mizoribine	13.5 μM (MERS-CoV)	[18]
Mizoribine	62 μM (SARS-CoV)	[18]

Acyclovir fleximer	23 μM (MERS-CoV)	[41]
Acyclovir fleximer	8.8 μM (HCoV-NL63)	[41]